Cell Therapeutics Responding To Inquiry Into Trisenox Off-Label Promotions
This article was originally published in The Pink Sheet Daily
Executive Summary
Seattle, Wash. U.S. attorney's office is investigating marketing practices for CTI's leukemia agent. The company's recent 10-Q filing acknowledges that Trisenox is "largely" prescribed off-label and some instances of off-label promotions have "likely" occurred.